Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

1 September 2024 (09:27 - 09:45)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Ahmad Masri

Oregon Health & Science University Medical Group, Portland (United States of America)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Doctor C. Ho (Boston, US)

Presentation thumbnail

Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

Doctor P. Garcia-Pavia (Majadahonda, ES)

Abstract Slides Video

Presentation thumbnail

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Doctor C. Coats (Glasgow, GB)

Abstract Slides Video

Presentation thumbnail

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Mr B. Van Driel (Amsterdam, NL)

Abstract Slides Video

Access the full session

Session thumbnail

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

The Event

Event poster

ESC Congress 2024

1 September 2024 09:27 CET

You may be interested in

Congress Presentation

Panel discussion and Q&A

Congress Session

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Congress Session

Navigating the evolving therapeutic landscape for obstructive hypertrophic cardiomyopathy (HCM)

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources